Clinical Trial Update: A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update assessing safety, tolerability, and mechanism of ALN-PNP siRNA in adults with nonalcoholic fatty liver disease and a genetic risk …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• ALN-PNP siRNA (ALN-PNP siRNA)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Status: COMPLETED